GE HealthCare Technologies Forecast, price target & analysts
GE HealthCare Technologies Target price 2025 - Analyst rating & recommendation
GE HealthCare Technologies Classifications & Recommendation:
GE HealthCare Technologies Price Target
| Target Price | $97.18 |
| Price | $68.07 |
| Potential | 42.76% |
| Number of Estimates | 17 |
| 17 Analysts have issued a price target GE HealthCare Technologies 2026 . The average GE HealthCare Technologies target price is $97.18. This is 42.76% higher than the current stock price. The highest price target is $115.00 68.94% , the lowest is $74.00 8.71% . | |
| A rating was issued by 21 analysts: 15 Analysts recommend GE HealthCare Technologies to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the GE HealthCare Technologies stock has an average upside potential 2026 of 42.76% . Most analysts recommend the GE HealthCare Technologies stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2028
17 Analysts have issued a sales forecast GE HealthCare Technologies 2025 . The average GE HealthCare Technologies sales estimate is $20.0b . This is 1.68% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $20.3b 3.33% , the lowest is $19.8b 0.85% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $19.7b | 0.61% |
|---|---|---|
| 2025 | $20.0b | 1.68% |
| 2026 | $20.9b | 4.70% |
| 2027 | $21.9b | 4.66% |
| 2028 | $22.9b | 4.58% |
13 Analysts have issued an GE HealthCare Technologies EBITDA forecast 2025. The average GE HealthCare Technologies EBITDA estimate is $3.9b . This is 11.59% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.1b 18.14% , the lowest is $3.7b 6.01% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $3.5b | 4.06% |
|---|---|---|
| 2025 | $3.9b | 9.41% |
| 2026 | $4.2b | 7.76% |
| 2027 | $4.5b | 7.19% |
| 2028 | $4.8b | 7.62% |
EBITDA Margin
| 2024 | 17.97% | 3.43% |
|---|---|---|
| 2025 | 19.34% | 7.60% |
| 2026 | 19.91% | 2.95% |
| 2027 | 20.39% | 2.41% |
| 2028 | 20.98% | 2.89% |
11 GE HealthCare Technologies Analysts have issued a net profit forecast 2025. The average GE HealthCare Technologies net profit estimate is $2.0b . This is 2.85% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.3b 17.05% , the lowest is $1.9b 6.45% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $2.0b | 43.71% |
|---|---|---|
| 2025 | $2.0b | 2.85% |
| 2026 | $2.3b | 11.75% |
| 2027 | $2.6b | 15.25% |
| 2028 | $3.0b | 13.33% |
Net Margin
| 2024 | 10.08% | 42.83% |
|---|---|---|
| 2025 | 10.20% | 1.18% |
| 2026 | 10.88% | 6.67% |
| 2027 | 11.99% | 10.20% |
| 2028 | 12.99% | 8.34% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
11 Analysts have issued a GE HealthCare Technologies forecast for earnings per share. The average GE HealthCare Technologies EPS is $4.46 . This is 2.76% higher than earnings per share in the financial year 2024. The highest EPS forecast is $5.08 17.05% , the lowest is $4.06 6.45% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $4.34 | 43.71% |
|---|---|---|
| 2025 | $4.46 | 2.76% |
| 2026 | $4.99 | 11.88% |
| 2027 | $5.75 | 15.23% |
| 2028 | $6.52 | 13.39% |
P/E ratio
| Current | 15.68 | 45.00% |
|---|---|---|
| 2025 | 15.25 | 2.74% |
| 2026 | 13.65 | 10.49% |
| 2027 | 11.84 | 13.26% |
| 2028 | 10.45 | 11.74% |
Based on analysts' sales estimates for 2025, the GE HealthCare Technologies stock is valued at an EV/Sales of 1.89 and an P/S ratio of 1.56 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.92 | 19.67% |
|---|---|---|
| 2025 | 1.89 | 1.42% |
| 2026 | 1.81 | 4.49% |
| 2027 | 1.73 | 4.45% |
| 2028 | 1.65 | 4.38% |
P/S ratio
| Current | 1.58 | 21.12% |
|---|---|---|
| 2025 | 1.56 | 1.65% |
| 2026 | 1.49 | 4.49% |
| 2027 | 1.42 | 4.46% |
| 2028 | 1.36 | 4.38% |
GE HealthCare Technologies...
Current GE HealthCare Technologies Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 23 2025 |
| Goldman Sachs |
Neutral
➜
Buy
|
Upgrade | Mar 11 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Feb 14 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Feb 13 2025 |
| Jefferies |
Hold
➜
Buy
|
Upgrade | Jan 08 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 31 2024 |
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Oct 01 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 23 2025 |
|
Upgrade
Goldman Sachs:
Neutral
➜
Buy
|
Mar 11 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Feb 14 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Feb 13 2025 |
|
Upgrade
Jefferies:
Hold
➜
Buy
|
Jan 08 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 31 2024 |
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Oct 01 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
